GSK plc (LON:GSK) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of GSK plc (LON:GSK) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is GBX 1,805.83 ($23.10).

Several equities analysts have issued reports on GSK shares. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank decreased their target price on GSK from GBX 1,820 ($23.28) to GBX 1,600 ($20.47) and set a “buy” rating for the company in a research report on Friday, November 29th.

GSK Price Performance

Shares of GSK opened at GBX 1,509 ($19.30) on Wednesday. The firm has a market capitalization of £61.23 billion, a price-to-earnings ratio of 24.38, a PEG ratio of 1.24 and a beta of 0.31. The firm’s fifty day simple moving average is GBX 1,398.01 and its 200-day simple moving average is GBX 1,447.27. GSK has a twelve month low of GBX 1,282.50 ($16.41) and a twelve month high of GBX 1,823.50 ($23.33). The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.82) per share, with a total value of £19,725 ($25,233.47). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.59), for a total value of £1,753,088.09 ($2,242,660.98). 1.61% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.